Treatments For Mild Cognitive Impairment Unlikely To Reduce Payer Costs – OptumInsight Exec
Executive Summary
Mild cognitive impairment has become an important focus in research on treating Alzheimer’s disease, based on the drive toward early intervention. But a lack of data on the condition complicates the development of economic models that could persuade payers about the cost effectiveness of treatments.
You may also be interested in...
Medicare Panel Finds Little Support For Amyloid PET Imaging Changes
MedCAC panel has limited confidence that there is enough evidence to show beta amyloid positron emission tomography imaging of the brain changes health outcomes. The vote does not bode well for the technology’s coverage proposal due in July.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.